Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug

Q: How long will it take to read this news story?

The story "Dr Reddy&#039;s, Hetero sign voluntary licenses with Gilead for HIV drug" has 729 words across 33 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Dr Reddy&#039;s, Hetero sign voluntary licenses with Gilead for HIV drug" was covered 4 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 266 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22851620</li><li>URL: https://beamstart.com/news/dr-reddys-hetero-sign-voluntary-17278853101940</li></ul>

Business Standard Logo Business Standard 4h ago

Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug - Business Standard

Quick Summary:

Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022.

The medicine had been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat COVID-19 patients.

Earlier in 2020, Gilead had signed voluntary licensing agreements with Indian firms like Cipla, Jubilant Life Sciences, Hetero, and Mylan for the manufacturing and distribution of Remdesivir, a therapy for COVID-19.